Chemoinformaics analysis of (1S,2R,9S,10S)-7,15-DIAZATETRACYCLO[7.7.1.02,7.010,15]HEPTADECAN-6-ONE
| Molecular Weight | 248.37 | nRot | 0 |
| Heavy Atom Molecular Weight | 224.178 | nRig | 21 |
| Exact Molecular Weight | 248.189 | nRing | 4 |
| Solubility: LogS | -4.046 | nHRing | 4 |
| Solubility: LogP | 2.496 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 42 | No. of Aliphatic Hetero Cycles | 4 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 4 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 4 |
| No. of Nitrogen atom | 2 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 44.055 |
| nHD | 0 | BPOL | 28.365 |
| QED | 0.681 |
| Synth | 4.717 |
| Natural Product Likeliness | 1.466 |
| NR-PPAR-gamma | 0.766 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.876 |
| Pgp-sub | 0.002 |
| HIA | 0.004 |
| CACO-2 | -4.713 |
| MDCK | 0.0000307 |
| BBB | 0.853 |
| PPB | 0.884574 |
| VDSS | 0.635 |
| FU | 0.0743151 |
| CYP1A2-inh | 0.061 |
| CYP1A2-sub | 0.604 |
| CYP2c19-inh | 0.406 |
| CYP2c19-sub | 0.933 |
| CYP2c9-inh | 0.071 |
| CYP2c9-sub | 0.541 |
| CYP2d6-inh | 0.059 |
| CYP2d6-sub | 0.764 |
| CYP3a4-inh | 0.151 |
| CYP3a4-sub | 0.746 |
| CL | 9.405 |
| T12 | 0.196 |
| hERG | 0.119 |
| Ames | 0.051 |
| ROA | 0.266 |
| SkinSen | 0.817 |
| Carcinogencity | 0.717 |
| EI | 0.017 |
| Respiratory | 0.872 |
| NR-Aromatase | 0.668 |
| Antiviral | Yes |
| Prediction | 0.789944 |